Moderna Announces Data to be Presented at ESMO Congress 2025
Moderna (NASDAQ:MRNA) announced the acceptance of three abstracts for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin from October 17-21, 2025. The presentations include a mini oral presentation on mRNA-4359 focusing on clinical outcomes in melanoma treatment, and two poster presentations on intismeran autogene (V940/mRNA-4157), which is being jointly developed with Merck.
The presentations will cover studies involving checkpoint inhibitor-resistant melanoma treatment, non-muscle-invasive bladder cancer therapy, and first-line therapy for advanced melanoma. Moderna will also host an analyst event during the congress, with details to be announced later.
Moderna (NASDAQ:MRNA) ha annunciato l'accettazione di tre abstract per la presentazione al Congresso 2025 della European Society for Medical Oncology (ESMO) che si terrà a Berlino dal 17 al 21 ottobre 2025. Le presentazioni includono una mini presentazione orale su mRNA-4359 focalizzata sui risultati clinici nel trattamento del melanoma, e due presentazioni poster su intismeran autogene (V940/mRNA-4157), sviluppato congiuntamente con Merck.
Le presentazioni riguarderanno studi sul trattamento del melanoma resistente agli inibitori del checkpoint, la terapia per il carcinoma della vescica non muscolo-invasivo e la terapia di prima linea per il melanoma avanzato. Moderna organizzerà inoltre un evento per analisti durante il congresso, con dettagli che saranno comunicati successivamente.
Moderna (NASDAQ:MRNA) anunció la aceptación de tres resúmenes para su presentación en el Congreso 2025 de la Sociedad Europea de Oncología Médica (ESMO) que se celebrará en Berlín del 17 al 21 de octubre de 2025. Las presentaciones incluyen una mini presentación oral sobre mRNA-4359 centrada en los resultados clínicos en el tratamiento del melanoma, y dos presentaciones en formato póster sobre intismeran autógeno (V940/mRNA-4157), desarrollado conjuntamente con Merck.
Las presentaciones cubrirán estudios relacionados con el tratamiento del melanoma resistente a inhibidores de puntos de control, la terapia para el cáncer de vejiga no músculo-invasivo y la terapia de primera línea para melanoma avanzado. Moderna también organizará un evento para analistas durante el congreso, cuyos detalles se anunciarán más adelante.
모더나 (NASDAQ:MRNA)는 2025년 10월 17일부터 21일까지 베를린에서 열리는 2025 유럽종양학회(ESMO) 총회에서 발표할 세 편의 초록이 채택되었음을 발표했습니다. 발표 내용에는 흑색종 치료의 임상 결과에 중점을 둔 mRNA-4359에 대한 미니 구두 발표와 Merck와 공동 개발 중인 intismeran autogene (V940/mRNA-4157)에 관한 두 편의 포스터 발표가 포함됩니다.
발표는 면역관문 억제제 저항성 흑색종 치료, 비근육침윤성 방광암 치료, 진행성 흑색종 1차 치료에 관한 연구를 다룰 예정입니다. 또한 모더나는 총회 기간 중 애널리스트 이벤트를 개최할 예정이며, 자세한 내용은 추후 공지될 예정입니다.
Moderna (NASDAQ:MRNA) a annoncé l'acceptation de trois résumés pour présentation au Congrès 2025 de la Société Européenne d'Oncologie Médicale (ESMO) qui se tiendra à Berlin du 17 au 21 octobre 2025. Les présentations comprennent une mini présentation orale sur mRNA-4359 axée sur les résultats cliniques dans le traitement du mélanome, ainsi que deux présentations par affiches sur intismeran autogène (V940/mRNA-4157), développé conjointement avec Merck.
Les présentations porteront sur des études concernant le traitement du mélanome résistant aux inhibiteurs de points de contrôle, la thérapie du cancer de la vessie non invasif musculaire, et la thérapie de première ligne pour le mélanome avancé. Moderna organisera également un événement pour les analystes durant le congrès, dont les détails seront annoncés ultérieurement.
Moderna (NASDAQ:MRNA) gab die Annahme von drei Abstracts zur Präsentation auf dem ESMO-Kongress 2025 der European Society for Medical Oncology bekannt, der vom 17. bis 21. Oktober 2025 in Berlin stattfindet. Die Präsentationen umfassen eine kurze mündliche Präsentation zu mRNA-4359, die sich auf klinische Ergebnisse bei der Behandlung von Melanomen konzentriert, sowie zwei Posterpräsentationen zu intismeran autogene (V940/mRNA-4157), das gemeinsam mit Merck entwickelt wird.
Die Präsentationen behandeln Studien zur Behandlung von Melanomen, die gegen Checkpoint-Inhibitoren resistent sind, zur Therapie bei nicht muskelinvasivem Blasenkrebs und zur Erstlinientherapie bei fortgeschrittenem Melanom. Moderna wird während des Kongresses auch eine Analystenveranstaltung ausrichten, deren Details später bekannt gegeben werden.
- None.
- None.
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025 in Berlin, Germany. This includes a mini oral presentation on mRNA-4359, Moderna's investigational mRNA-based therapy designed to elicit T-cell immune responses against tumor and immunosuppressive cells, as well as two poster presentations on intismeran autogene (V940/mRNA-4157). Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
The details of the presentations are as follows:
Presentation #1515MO: Clinical Outcomes and PD-L1 Expression Analyses from a Trial of mRNA-4359 Plus Pembrolizumab in Checkpoint Inhibitor-Resistant/Refractory (CPI-R/R) Melanoma
Mini Oral Presentation: October 17, 2025, 2:00 - 3:30 PM CET
Location: Nuremberg Auditorium - Hall 5.2
Presenter: David J. Pinato
Presentation #3135eTiP: INTerpath-011: Phase 2 study of intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guérin (BCG) versus BCG alone for high-risk (HR) non-muscle-invasive bladder cancer (NMIBC)
Presenter: Petros Grivas
Presentation #1684TiP: Intismeran autogene (V940/mRNA-4157) + pembrolizumab versus pembrolizumab alone as first-line therapy for advanced melanoma: the phase 2 INTerpath-012 study
Presenter: Paolo A. Ascierto
Moderna Investor Event
Moderna will host an analyst event while at ESMO. Details of the event to follow.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
When and where will Moderna present at ESMO Congress 2025?
What studies will Moderna (MRNA) present at ESMO 2025?
Who is developing intismeran autogene (V940/mRNA-4157)?
Will Moderna host an investor event at ESMO 2025?
